News Decision to axe Afinitor 'confirms worst fears’ for Cancer D... NICE reviewing 'legacy drugs' to free up CDF funds
News Xalkori gains NICE approval after price cut NICE approval secured against background of renewed controversy
Views & Analysis NICE plans to charge for appraisals – but pharma wants refor... Will NICE introduce fees for pharma companies' TAs from next year?
News NICE recommends Amgen’s melanoma treatment after price cut Drug only approved when systemic immunotherapies are not suitable
News NHS under fire for rationing hep C drugs NHS England tried to interfere with NICE appraisals, says BMJ.
News England's new-look Cancer Drugs Fund begins But concerns remain about access to oncology medicines.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
